| Title |
New treatment strategies for HPV-positive head and neck cancer
|
|---|---|
| Published in |
European Archives of Oto-Rhino-Laryngology, August 2013
|
| DOI | 10.1007/s00405-013-2603-0 |
| Pubmed ID | |
| Authors |
B. Kofler, S. Laban, C. J. Busch, B. Lörincz, R. Knecht |
| Abstract |
Epidemiological studies show an increasing incidence of human papilloma virus-associated oropharyngeal cancer. HPV-positive head and neck squamous cell carcinoma (HNSCC) is recognized as a special subgroup of HNSCC. Because HPV-positive patients are often younger and have an outstanding prognosis, long-term toxicities of therapy have become an important issue. Current clinical trials focus on a reduction of treatment-related toxicity and the development of HPV-specific therapies. New treatment strategies include a dose reduction of radiotherapy, the use of cetuximab instead of cisplatin for chemoradiation and transoral robotic surgery (TORS). Increasing comprehension of the molecular background of HPV-associated HNSCC has also lead to more specific treatment attempts including immunotherapeutic strategies. Whereas recently published data shed light on immune mechanisms resulting in a tolerogenic niche for HPV and HPV-associated HNSCC, other studies focus on specific vaccination of HPV-positive HNSCC. This study will summarize current therapy approaches and illustrate ongoing clinical trials in the field of HPV-positive HNSCC. |
Mendeley readers
The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | <1% |
| Ecuador | 1 | <1% |
| France | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 98 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 17 | 17% |
| Student > Bachelor | 14 | 14% |
| Researcher | 10 | 10% |
| Student > Ph. D. Student | 10 | 10% |
| Other | 9 | 9% |
| Other | 24 | 24% |
| Unknown | 18 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 44 | 43% |
| Biochemistry, Genetics and Molecular Biology | 13 | 13% |
| Agricultural and Biological Sciences | 10 | 10% |
| Nursing and Health Professions | 2 | 2% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 2% |
| Other | 5 | 5% |
| Unknown | 26 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 January 2021.
All research outputs
#6,406,240
of 22,758,963 outputs
Outputs from European Archives of Oto-Rhino-Laryngology
#327
of 3,056 outputs
Outputs of similar age
#54,794
of 197,462 outputs
Outputs of similar age from European Archives of Oto-Rhino-Laryngology
#4
of 37 outputs
Altmetric has tracked 22,758,963 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 3,056 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 197,462 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.